BP
DXCM icon

Broadleaf Partners’s DexCom DXCM Stock Holding History

Broadleaf Partners’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-82,305
Closed -$9.33M – 81
2024
Q2 		$9.33M Sell
82,305
-507
-0.6% -$64.1K 2.26% 17
2024
Q1 		$11.5M Buy
82,812
+1,010
+1% +$127K 2.94% 10
2023
Q4 		$10.2M Sell
81,802
-2,110
-3% -$216K 2.98% 10
2023
Q3 		$7.83M Buy
83,912
+24,642
+42% +$2.78M 2.61% 15
2023
Q2 		$7.62M Buy
+59,270
New +$7.17M 2.49% 15
2022
Q2 		– Sell
-33,016
Closed -$4.22M – 66
2022
Q1 		$4.22M Buy
+33,016
New +$3.61M 1.41% 30

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Broadleaf Partners's DXCM Position: Q3 2024 in Review

Broadleaf Partners sold out of DexCom (DXCM) in Q3 2024, closing a stake of 82,305 shares — an estimated $9.33M sold.

Broadleaf Partners first reported a position in DXCM in Q1 2022 and held it in 6 quarters. The position peaked at $11.5M in Q1 2024. 890 funds tracked by Wall St. Rank hold DXCM as of Q3 2024.

  • Broadleaf Partners reported no remaining DexCom position as of Q3 2024 after selling out during the quarter.
  • Broadleaf Partners sold 82,305 DexCom shares in Q3 2024, an estimated $9.33M.
  • Broadleaf Partners first reported a position in DexCom in Q1 2022 and held it in 6 quarters.
  • Broadleaf Partners's DexCom position peaked at $11.5M in Q1 2024.
  • 890 funds tracked by Wall St. Rank held DexCom as of Q3 2024.

Based on Broadleaf Partners's 13F filing for Q3 2024, filed 12 Nov 2024.